CABA News and Press, Cabaletta Bio Inc. From 08/08/25

Cabaletta Bio Inc. (CABA) is expected to report $-0.71 for Q2 2025

2025-08-07 12:49:45 ET Read the full article on Seeking Alpha For further details see: Cabaletta Bio files $240M mixed securities shelf

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 c...

2025-06-11 10:09:23 ET More on Cabaletta Bio Cabaletta Bio: Sector Headwinds And Funding Issues... But Also Some Clear Clinical Direction Cabaletta Bio slides on proposed securities offering Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earn...

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients w...

2025-06-11 09:49:25 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Cabaletta Bio: Sector Headwinds And Funding Issues... But Also Some Clear Clinical Direction

2025-06-11 06:29:06 ET Cabaletta Bio ( NASDAQ: CABA ) shares fell 20% in premarket trade on Wednesday after the biotechnology company proposed a public offering of mixed securities. The company plans to offer shares of its common stock and accompanying warrants to purchase...

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients w...

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients wit...

2025-06-06 11:09:17 ET Investment Overview When I last covered Autolus Therapeutics plc ( AUTL ) for Seeking Alpha back in September last year, it was to make a Bull case for its shares, based on the UK-based biotech's upcoming PDUFA date for its autologous CAR-T cell th...